BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng KI, Liu WY, Pan XY, Ma HL, Zhu PW, Wu XX, Targher G, Byrne C, Wang XD, Chen YP, Lu F, Zheng MH. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Res Care 2020;8:e001174. [PMID: 32139603 DOI: 10.1136/bmjdrc-2020-001174] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeng Y, He H, An Z. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. Dis Markers 2022;2022:1254014. [PMID: 35811662 DOI: 10.1155/2022/1254014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang Q, Zhou D, Wang M, Zhu M, Chen P, Li H, Lu M, Zhang X, Shen X, Liu T, Chen L. A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. Front Med 2022;9:900794. [DOI: 10.3389/fmed.2022.900794] [Reference Citation Analysis]
3 Chen ZW, Xiao HM, Ye X, Liu K, Rios RS, Zheng KI, Jin Y, Targher G, Byrne CD, Shi J, Yan Z, Chi XL, Zheng MH. A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. Hepatobiliary Surg Nutr 2022;11:212-26. [PMID: 35464279 DOI: 10.21037/hbsn-21-23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Segura-Azuara NLÁ, Varela-Chinchilla CD, Trinidad-Calderón PA. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Front Med (Lausanne) 2021;8:774079. [PMID: 35096868 DOI: 10.3389/fmed.2021.774079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yao M, Wang L, Wang J, Liu Y, Liu S, Zhao J, Lu F, Tu W. Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/4253566] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Peng Y, Zeng Q, Wan L, Ma E, Li H, Yang X, Zhang Y, Huang L, Lin H, Feng J, Xu Y, Li J, Liu M, Liu J, Lin C, Sun Z, Cheng G, Zhang X, Liu J, Li D, Wei M, Mo Y, Mu X, Deng X, Zhang D, Dong S, Huang H, Fang Y, Gao Q, Yang X, Wu F, Zhong H, Wei C. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun 2021;12:7004. [PMID: 34853313 DOI: 10.1038/s41467-021-27309-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Li Y, Yang Y, Li Y, Zhang P, Ge G, Jin J, Du T, Ma M, Na L, Ding L, Sheng H. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis. J Int Med Res 2021;49:3000605211055378. [PMID: 34772312 DOI: 10.1177/03000605211055378] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu J, Huang Y, Li T, Jiang Z, Zeng L, Hu Z. The role of the Golgi apparatus in disease (Review). Int J Mol Med 2021;47:38. [PMID: 33537825 DOI: 10.3892/ijmm.2021.4871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yao MJ, Wang LJ, Liu S, Lu FM. Application of serum Golgi protein-73 in the management of chronic liver disease. Chin Med J (Engl) 2020;134:777-9. [PMID: 33323825 DOI: 10.1097/CM9.0000000000001296] [Reference Citation Analysis]
13 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One 2020;15:e0238717. [PMID: 32915852 DOI: 10.1371/journal.pone.0238717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
15 Qiao ZP, Zheng KI, Zhu PW, Gao F, Ma HL, Li G, Li YY, Targher G, Byrne CD, Zheng MH. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutr Metab Cardiovasc Dis 2020;30:1820-5. [PMID: 32636124 DOI: 10.1016/j.numecd.2020.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]